Importantly, our data emphasized KRAS potential role in samples with ARID1A or PIK3CA mutation in OCCC, identified LRP1B mutation group only occurred in samples with non-ARID1A truncation mutation, distinguished the potential carcinogens-exposed of those tumors by mutational signatures and unearthed several novel drivers in CNV level that might essentially contribute to OCCC tumor progression. This evidence concerns the gene PIK3CA and neoplasm.